Co-Diagnostics, Inc. (CODX)

Acelyrin Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	0.57	0.77	0.99	34.22	97.89	74.55
Other Revenue	2.93	3.15	5.82	-	-	-
Revenue	3.5	3.92	6.81	34.22	97.89	74.55
Revenue Growth (YoY)	-47.63%	-42.53%	-80.09%	-65.04%	31.30%	34579.89%
Cost of Revenue	0.79	1	4.18	5.48	11.57	16.59
Gross Profit	2.71	2.92	2.63	28.74	86.31	57.96
Selling, General & Admin	19.59	20.64	21.14	21.61	24.95	12.94
Research & Development	20.17	20.98	22.96	17.44	14.96	3.19
Operating Expenses	41.09	43	45.33	40.33	40.25	16.27
Operating Income	-38.37	-40.08	-42.71	-11.59	46.06	41.69
Interest & Investment Income	0.74	1.09	1.16	0.7	0.05	0.1
Earnings From Equity Investments	-0.12	-0.19	0.1	-0.33	-0.43	0.78
EBT Excluding Unusual Items	-37.75	-39.18	-41.44	-11.22	45.68	42.57
Impairment of Goodwill	-	-	-	-15.39	-	-
Gain (Loss) on Sale of Investments	0.94	0.87	2.24	-	-	-
Gain (Loss) on Sale of Assets	0.01	0.01	-0	-0.14	-0.04	-0
Other Unusual Items	0.98	0.71	1.09	7.9	-	-
Pretax Income	-35.81	-37.58	-38.11	-18.85	45.64	42.57
Income Tax Expense	0.05	0.06	-2.78	-4.61	8.98	0.09
Net Income	-35.86	-37.64	-35.33	-14.24	36.66	42.48
Net Income to Common	-35.86	-37.64	-35.33	-14.24	36.66	42.48
Net Income Growth	-	-	-	-	-13.70%	-
Shares Outstanding (Basic)	31	30	29	31	29	27
Shares Outstanding (Diluted)	31	30	29	31	30	28
Shares Change (YoY)	4.93%	3.37%	-6.77%	5.27%	6.80%	67.10%
EPS (Basic)	-1.16	-1.24	-1.20	-0.45	1.27	1.59
EPS (Diluted)	-1.17	-1.24	-1.20	-0.45	1.23	1.52
EPS Growth	-	-	-	-	-19.08%	-
Free Cash Flow	-29.85	-29.9	-23.45	5.14	40.41	27.39
Free Cash Flow Per Share	-0.97	-0.99	-0.80	0.16	1.35	0.98
Gross Margin	77.52%	74.48%	38.56%	83.98%	88.17%	77.75%
Operating Margin	-1097.15%	-1023.75%	-626.92%	-33.88%	47.06%	55.93%
Profit Margin	-1025.29%	-961.37%	-518.68%	-41.61%	37.45%	56.98%
Free Cash Flow Margin	-853.39%	-763.79%	-344.20%	15.02%	41.28%	36.74%
EBITDA	-37.05	-38.7	-41.48	-10.31	46.4	41.83
EBITDA Margin	-	-	-	-30.13%	47.40%	56.11%
D&A For EBITDA	1.33	1.38	1.23	1.28	0.34	0.14
EBIT	-38.37	-40.08	-42.71	-11.59	46.06	41.69
EBIT Margin	-	-	-	-33.88%	47.06%	55.93%
Effective Tax Rate	-	-	-	-	19.67%	0.21%
Revenue as Reported	3.5	3.92	6.81	34.22	-	-

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q